A retrospective evaluation of long-term fluspirilene (IMAP) treatment.
Fluspirilene proved to be a very useful drug in the basic maintenance therapy of 21 chronic schizophrenic patients (ages 16-71 years), who received individually adjusted doses weekly during their hospitalization and during the subsequent follow-up period. The follow-up data analysis showed that the antipsychotic efficacy of the drug after prolonged (8-21.5 months) treatment was nicely maintained, that the patients' socio-professional integration had improved significantly, while a small decrease in dosage proved possible in several cases. The incidence of side-effects remained low, and no signs of accumulation or toxicity could be detected.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000553:Ambulatory Care; D005260:Female; D005484:Fluspirilene / Q000009:adverse effects / Q000627:therapeutic use*; D006760:Hospitalization; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012559:Schizophrenia / Q000188:drug therapy*; D013141:Spiro Compounds / Q000627:therapeutic use*; D013997:Time Factors
D013141:Spiro Compounds; D005484:Fluspirilene